Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 23 tags : Disease save search
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
Published: 2021-08-23 (Crawled : 21:00) - globenewswire.com
CYCN | $3.37 12.62% 2.4K
|
Health Technology
|
| O: 2.13%
H: 7.29%
C: 5.9%
disease alzheimer alzheimer’s alzheimer's disease alzheimer's biomarkers
Rise in Prevalence of Dry Eye Disease Due to Ageing, Use of Computers to Drive Dry Eye Disease Treatment Market, Says TMR
Published: 2021-08-23 (Crawled : 14:00) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.57%
H: 0.42%
C: -0.12%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.31%
H: 0.3%
C: -0.44%
BHC | $8.63 -1.48% 0.0% 3.2M
|
Health Technology
|
| O: 1.07%
H: 0.6%
C: -0.11%
dry eye disease treatment eye eye disease
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
AMRX | $5.55 0.54% 0.54% 1.1M
|
Health Technology
|
| O: 1.44%
H: 9.13%
C: 7.3%
disease parkinson phase 3
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
Published: 2021-08-23 (Crawled : 12:00) - biospace.com/
SNGX | $0.4673 21.03% 17.38% 130M
|
Health Technology
|
| O: 7.22%
H: 1.4%
C: 0.49%
disease vaccine marburg
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
Published: 2021-08-23 (Crawled : 12:00) - biospace.com/
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 1.14%
H: 0.71%
C: -0.46%
disease food drug
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
Published: 2021-08-23 (Crawled : 12:00) - globenewswire.com
ATHA | $2.045 -16.19% -19.32% 370K
|
Health Technology
|
| O: 0.94%
H: 6.01%
C: 5.7%
disease alzheimer ath-1017 alzheimer’s alzheimer's disease alzheimer's biomarkers
Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases
Published: 2021-08-23 (Crawled : 12:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 1.45%
H: 0.95%
C: 0.89%
disease liver disease gene therapies collaboration license liver gene therapy therapy rare
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.